KaloBios Completes Dosing in Phase I Study for Inflammatory Diseases
Posted on: Tuesday, 29 April 2008, 06:00 CDT
KaloBios Pharmaceuticals has completed dosing subjects in a placebo-controlled, single-dose, dose-escalation Phase I clinical trial of its third drug candidate, KB003.
KB003 is a humaneered monoclonal antibody targeted to GM-CSF, and it shares the same epitope (target) and pharmacokinetic properties with KB002, its chimeric (mouse) precursor. They are part of a major development program that collectively includes five Phase I and Phase II proof-of-principle clinical trials for inflammation-related diseases, including persistent asthma and rheumatoid arthritis.
Animal studies have suggested that the drug candidate also has potential in multiple sclerosis, chronic obstructive pulmonary disease, psoriasis, and other indications.
Tillman Pearce, chief medical officer of KaloBios, said: "We have treated our last patient in our Phase I/II rheumatoid arthritis trial, are making great progress with our Phase II persistent asthma trials, and have other confidential clinical trials underway. We can now leverage the data that we obtain from these KB002 studies to guide our KB003 multiple-dose trials."
Source: Datamonitor
Related Articles
- Apthera Announces Optimal Dose and Schedule of NeuVax for Phase III Clinical Trial in Breast Cancer
- OrthoLogic Announces Completion of Dosing for Second AZX100 Phase 1 Human Clinical Trial in Dermal/Hypertrophic Scarring
- OrthoLogic Announces Initiation of Dosing for Second AZX100 Phase 1 Human Clinical Trial in Dermal/Hypertrophic Scarring
- Generex Biotechnology Phase I Trial Results for Novel Immunotherapy Vaccine in Breast Cancer Patients Presented At ASCO
- OrthoLogic Announces Initiation of Dosing for AZX100 Phase 1 Human Clinical Trial in Dermal/Hypertrophic Scarring
- Tranzyme Pharma Initiates Dosing of Patients in a Multi-National Phase IIb Clinical Trial With Its Novel Ghrelin Agonist, TZP-101, for Post-Operative Ileus
- Manhattan Pharmaceuticals Successfully Completes Dosing Portion of Two Phase 2a Clinical Trials of Oral Oleoyl-Estrone for Obesity
- Amarin Reports Initiation of Enrollment and First Patient Dosing in Pivotal Phase III Clinical Trials for Miraxion in Huntington's Disease
- BioVex Begins Phase I/II Clinical Trial of ImmunoVEXtrimelan With the Dosing of Malignant Melanoma Patient
- ChemoCentryx Initiates Phase II Clinical Trial of Traficet-EN in Inflammatory Bowel Disease; Results From Phase I Clinical Studies Confirm Once-Daily Dosing Regimen
 |
 |
User Comments (0)
RSS Feeds